A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.

Trial Details

NCT ID
NCT06936735
Phase
PHASE1
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • HS-20108 Monotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Men or women aged more than or equal to (≥) 18 years.
  • Participants with pathologically confirmed advanced solid tumors.
  • At least one measurable lesion in accordance with RECIST 1.1
  • Fresh or archival tumor tissue available for submission.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →